Reports of Biochemistry and Molecular Biology

en Role of Visfatin in Chronic Kidney Disease: Diagnostic Potential and Association with Hemodialysis بیوشیمی Biochemistry مقالات اصلی Original Article <div style="text-align: justify;">Background: Chronic kidney disease (CKD) is a major cause of morbidity and mortality worldwide, often progressing silently until advanced stages. This study aimed to evaluate the diagnostic potential of serum visfatin levels and Nicotinamide Phosphoribosyl transferase (NAMPT) gene expression in peripheral blood mononuclear cells (PBMCs) among CKD patients, along with their correlation with disease severity and lipid profile. Methods: A case-control study included 30 CKD patients, divided into two subgroups: 15 end-stage renal disease (ESRD) patients undergoing hemodialysis (HD) and 15 non-dialysis patients. These patients were matched by age and body mass index (BMI) with 30 healthy subjects (HS). Serum visfatin, lipid profile, electrolytes, NAMPT gene expression, and other biochemical markers were measured. Results: This study showed significantly higher visfatin levels in CKD patients compared to HS, with the highest levels observed in the ESRD group undergoing HD (5.6±1.63 ng/mL compared with 3.5±1.4 ng/mL in CKD without HD, and 2.7±1.1 ng/mL in HS; p≤0.001). Similarly, NAMPT gene expression was significantly upregulated in CKD patients, with the highest expression in the HD group, correlating strongly with serum visfatin levels (r = 0.76, p≤0.001) and lipid profile markers, including triglycerides (r = 0.67, p=0.002) and low-density lipoprotein (LDL; r = 0.61, p=0.004). In CKD patients undergoing HD, visfatin levels showed a positive correlation with triglycerides and LDL levels, suggesting a link with dyslipidemia. No significant correlation was found between visfatin and highly sensitive C-reactive protein (hsCRP), urea, creatinine, or very-low-density lipoprotein (VLDL). Conclusion: These findings indicate that serum visfatin and NAMPT gene expression could serve as novel biomarkers for assessing CKD severity, particularly in patients undergoing hemodialysis, with potential implications for managing inflammation and cardiovascular risk in CKD.</div> Adipokines, Biological Markers, Inflammation, Dyslipidemias, Kidney Failure, Renal Dialysis. 57 68 http://rbmb.net/browse.php?a_code=A-10-1674-1&slc_lang=en&sid=1 Hawazin Aziz Hamim 100319475328460021965 100319475328460021965 No Department of Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Dunia Abdul Jabbar Satar 100319475328460021966 100319475328460021966 No Middle Technical University, Institute of Medical Technology, Baghdad, Iraq. Mastafa Heilo Jabber Al-Musawi 100319475328460021967 100319475328460021967 No Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Mina Shahriari-Khalaji 100319475328460021968 100319475328460021968 No Department of Biomedical Engineering, Rowan University, Glassboro, New Jersey, USA. Mohamadreza Tavakoli 100319475328460021969 100319475328460021969 No Department of Materials Engineering, Isfahan University of Technology, Isfahan, Iran. Marjan Mirhaj marjan.mirhaj@yahoo.com. 100319475328460021970 100319475328460021970 Yes Department of Materials Engineering, Isfahan University of Technology, Isfahan, Iran. Nisreen Ahmed Hamzah 100319475328460021971 100319475328460021971 No Department of Chemistry, College of Science, Sumer University, Iraq.